Equities researchers at StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY – Get Free Report) in a research report issued on Sunday. The brokerage set a “hold” rating on the stock.
NovaBay Pharmaceuticals Trading Up 48.9 %
NBY opened at $0.74 on Friday. The company has a fifty day simple moving average of $0.79 and a 200 day simple moving average of $2.49. The firm has a market cap of $800,680.00, a price-to-earnings ratio of -0.01 and a beta of 0.73. NovaBay Pharmaceuticals has a twelve month low of $0.36 and a twelve month high of $17.74.
NovaBay Pharmaceuticals (NYSE:NBY – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($1.37) EPS for the quarter. NovaBay Pharmaceuticals had a negative net margin of 91.86% and a negative return on equity of 744.33%. The company had revenue of $2.40 million for the quarter. On average, analysts forecast that NovaBay Pharmaceuticals will post -0.17 earnings per share for the current fiscal year.
Institutional Trading of NovaBay Pharmaceuticals
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
Featured Articles
- Five stocks we like better than NovaBay Pharmaceuticals
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- With Risk Tolerance, One Size Does Not Fit All
- MarketBeat Week in Review – 9/16 – 9/20
- How to Calculate Inflation Rate
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.